Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Deciding between broad market and sector funds depends on diversification needs and risk tolerance. This guide compares outcomes and helps you decide.
28,547 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Palantir posted 70% revenue growth in Q4 2025, led by US commercial gains and a robust free cash flow outlook. Trader...
Vistra reports record 2025 EBITDA and unveils a 2026 target that points to sustained growth. The company cites long-t...
Oil prices pressed higher on March 26, 2026, nearing the mid-$100s per barrel. The move highlights how current price ...
Rocket Lab has surged more than 350% in a year, but investors remain split on the sustainability of the rally as back...
European markets tumbled on Monday as new Middle East tensions joined the AI scare trade, pushing oil higher and risk...
A major brokerage lifts its price target for ASML to near $2,000, citing surging EUV demand from DRAM makers and a sw...
A sharp Friday selloff in tech stocks gave way to Monday gains as AI-driven names rebound, signaling that the trade’s...
Gap reported a Q4 beat on earnings but a sharp post-earnings slide as margins face tariff pressure. The company raise...
Investors confront a triple threat as rating concerns, tariff fights, and Middle East risk collide, putting Indonesia...
A new Xbox CEO rises amid a changing gaming landscape. Her career path—from janitorial work to coupon sales to the C-...
Disclosures reveal a major tether investor’s donations to a UK party backing pro-crypto policies now total about $16 ...